Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Q-Bot Fundraising

30 Jul 2024 07:00

RNS Number : 2950Y
NetScientific PLC
30 July 2024
 

RNS: 7.00 a.m. on 30 July 2024

 

NetScientific plc

 

(NetScientific, the Group or the Company)

 

Q-Bot Limited (Q-Bot) Fundraising

 

Issue of Shares and Total Voting Rights

 

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that portfolio company Q-Bot, a robotics-as-a-service construction tech company, has successfully closed a fundraising of £1.5 million (Fundraising).

Fundraising

The Fundraising was led and syndicated by EMV Capital, the Company's wholly owned venture capital and corporate finance firm, and includes a subscription for £1.25 million of new shares in the capital of Q-Bot and a loan facility of £250,000 (such loan facility amount being part of a re-financed loan of c.£785,000). It follows an initial fundraising earlier in 2024 of c.£1.4 million (also led and syndicated by EMV Capital) received from advance subscription agreements (ASAs) and a convertible loan agreement (CLA). The Fundraising will provide Q-Bot with working capital to progress its revised business plan, which includes rationalising its business into two separate divisions, an installations business and a technologies focused business. The planned restructuring allows the installations business to attract investment to reach break-even and accelerate growth, and the technologies business to operate on a standalone basis and exploit multiple existing and new US and EU growth opportunities to create further value.

The Group has participated directly in the Fundraising, including:

· a £349,968.22 subscription for Q-Bot shares, such amount to settled by the Company issuing to Q-Bot 411,727 new ordinary shares in the capital of the Company (Consideration Shares) at a price of £0.85 per New Share, a 35.0 per cent. premium to the closing price of the Company's ordinary shares on 29 July 2024; and

· a £198,143.92 advance subscription pursuant to an ASA, converting outstanding fees due to EMV Capital into Q-Bot shares.

EMV Capital's EMVC Evergreen EIS Fund has also participated in the ASA.

The Consideration Shares are subject to orderly market provisions such that if they are to be disposed of they must be sold through the Company's broker.

Following completion of the Fundraising, the total equity holding of the Group in Q-Bot is increased to 17.0 per cent, which equates to a post-investment fair value of £2.7 million, a decrease of 28.3 per cent. from the £3.8 million reported as at 31 December 2023. In addition, following the introduction of investors to Q-Bot by EMV Capital, the NetScientific third party assets under management with Q-Bot is 37.4 per cent. of the share capital, which equates to a post-investment fair value of £6.0 million, a decrease of 30.3 per cent. from the £8.6 million reported as at 31 December 2023. Such percentage holdings are based on issued share capital, and subject to dilution by the CLA and certain warrants and options.

Q-Bot is a well-known robotics and automation company in the growing Construction Tech and Climate Solutions area, with sales in the UK and Europe. Using AI and robotics, Q-Bot's insulation is deployed beneath suspended timber floors or to the underside of suspended concrete floors. A remotely operated robotic device applies a continuous layer of spray-foam insulation to the underside of the floor, resulting in a reduction in heat loss through the floor and a barrier to cold air draughts.

Q-Bot's advanced insulation has generated £11.6 million in revenues from nearly 5,000 installations in the UK (including through partners) and over £200,000 in revenues from installations in France. 

Following the Fundraising, Malcolm Groat, currently a non-executive investor director of Q-Bot, will become Chair of Q-Bot.

Dr Ilian Iliev, CEO of NetScientific and Investment Director of Q-Bot, commented:

"We are pleased to see Q-Bot close this fundraising. The company's technology licensing, and installations business units each have a route to break-even within this vast market, and we wish it every success in executing on its plans to grow the technology platform, including on an international scale, whilst servicing a high-quality existing UK sales pipeline."

Admission of Consideration Shares and Total Voting Rights

Application will be made for the Consideration Shares, which will rank pari passu with existing Ordinary Shares, to be admitted to AIM (Admission). It is expected that Admission will become effective and dealings will commence at 8.00 a.m. on or around 2 August 2024.

Following Admission, the total issued share capital of the Company will consist of 24,357,555 Ordinary Shares. The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company will be 24,357,555 Ordinary Shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The person responsible for arranging the release of this announcement on behalf of the Company is Edward Hooper, General Counsel and Executive Director of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO

Via Belvedere Communications

 

Panmure Liberum Limited (NOMAD and Broker)

 

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

Belvedere Communications

John West / Llewellyn Angus / Lily Pearce

 

+44 (0)20 7653 8702

 

About NetScientific

NetScientific plc (AIM: NSCI) is a deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally.

The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-efficient investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net www.netscientific.net  

 

About Q-Bot

Q-Bot, founded in 2012 by Tom Lipinski and Professor Peter Childs FREng, is a provider to the UK Government's Green Homes Local Authority Delivery Scheme, the Social Housing Decarbonisation Fund, Great British Insulation Scheme and Home Upgrade Grant. 

Q-Bot's floor insulation is installed in over 200 homes every month and to date the company has installed nearly 5,000 properties across the UK and Europe. The company works with over 50 registered social housing providers, energy companies such as E.ON and British Gas, as well as a network of accredited installers and property agents.

An average-sized UK household, insulated by Q-Bot, could typically save c.£850 per year in an electrically-heated home, and c.£270 a year in a gas-heated home. Studies show that the Q-Bot system reduces heat loss through the floor by 77% and cold draughts by 1/3 for the whole house. With retrofitting existing buildings seen as essential for the UK to reach Net Zero, a household using Q-Bot's solution can cut its annual CO emissions by an average 700 kg.

Q-Bot's work has received grant support from the UK Government and Innovate UK, and it has won numerous awards, including the CIBSE Building Performance Award and the Queen's Award for Enterprise (Innovation). 

www.q-bot.co

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURFFFIFDFIAFIS
Date   Source Headline
16th Sep 20242:31 pmRNSPDS: Updated Results, VERSATILE-002 Phase 2 Trial
13th Aug 20243:57 pmRNSPDS Biotech: Business Update and Q2 2024 Results
2nd Aug 202412:21 pmRNSReplacement RNS: PDS Biotech Aligns with FDA
2nd Aug 20247:00 amRNSPDS Biotech Aligns with FDA on Phase 3 Trial
30th Jul 20247:00 amRNSQ-Bot Fundraising
10th Jul 202410:48 amRNSResult of AGM
18th Jun 20247:00 amRNSNotice of AGM
14th Jun 20242:10 pmRNSTR-1
14th Jun 20247:00 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSPreliminary Results for the year ended 31 Dec 2023
31st May 20247:01 amRNSNotice of Results and Investor Presentation
31st May 20247:00 amRNSDeepTech Recycling: Fundraising, Business Update
28th May 20247:00 amRNSInvestment in Wanda, related party transactions
15th May 20242:32 pmRNSPDS Biotech: Business Update and Q1 2024 Results
13th May 20247:00 amRNSMartlet Capital: mandate and acquisition
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.